Executive SummarySupragen wants to developing drugs and vaccines around a class of proteins called superantigens, which can trigger a massive immune response so strong it can induce toxic shock syndrome and may be part of the pathogenesis of other autoimmune, inflammatory and infectious diseases.
You may also be interested in...
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.